<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               <BR>1 INDICATIONS AND USAGE<BR><BR>               <BR>                  OntakÂ® is indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor [see Warnings and Precautions (5.4)].<BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                        Ontak is a CD25-directed cytotoxin indicated for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor. (1)<BR><BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>